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Abstract: Obesity is defined as a chronic, complex, relapsing disease characterized by 
excessive adipose tissue. Obesity impacts an individual’s health by increasing complications 
such as prediabetes, type 2 diabetes mellitus (T2DM), hypertension, dyslipidemia, metabolic 
syndrome, cardiovascular disease, nonalcoholic fatty liver disease (NAFLD), cancers (eg 
endometrial), and obstructive sleep apnea (OSA). With the increase of obesity prevalence 
and its negative influences on individuals’ quality of life, there is a great need for therapy 
with a purpose to produce sustainable weight loss of more than 10% in order to improve or 
even reverse the progress of obesity related complications. The GLP-1 analogue, liraglutide 
reduce food consumption, promote weight reduction and improve metabolic functions. The 
primary mechanism of GLP-1 effect on food intake, metabolism, and weight reduction is 
mainly due to its actions on peripheral (vagal) and central pathways and activation of 
hindbrain and hypothalamus. The average weight reduction induced by liraglutide was 
significant and the weight loss was maintained as long as the patients on therapy. 
Liraglutide has advantages on weight loss maintenance and promoting cardiovascular disease 
(CVD) risk reduction, by decreasing systolic blood pressure and glycemic index. In this 
review, we aim to explain the mechanism of action of Liraglutide, its pharmacokinetic 
properties, its clinical impact on obesity and its safety and tolerability. 
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Obesity is defined as a chronic, complex and relapsing disease, characterised by excessive 
adipose tissue resulting in ill health. Obesity associated with adverse metabolic, biome-
chanical, and psychosocial health consequences.1,2 Previously obesity was merely con-
sidered a behavioral disorder or lifestyle choice caused by increased calorie intake or 
reduced physical activity. However, current evidence which considers obesity as a disease 
suggests that obesity is mainly caused by a disruption of homeostatic control of body 
weight and a failure to prevent excessive fat accumulation.3 Obesity is associated with 
impaired metabolic pathways along with disordered signaling of appetite, hence indivi-
duals with obesity experience symptoms that manifest as an increase in hunger and lack of 
fullness.4
Obesity is a multifactorial disease caused by many contributing factors such as 
biological, genetic, epigenetic, environmental, neurological, and hormonal. These 
cause an imbalance between caloric intake and energy expenditure.5,6 Obesity 
impacts an individual’s health by increasing complications such as prediabetes 
and type 2 diabetes mellitus (T2DM), hypertension, dyslipidemia, metabolic syn-
drome, cardiovascular disease, polycystic ovary syndrome (PCOS), nonalcoholic 
Correspondence: Heshma Alruwaili  
Email alruwaily85@hotmail.com
submit your manuscript | www.dovepress.com Clinical Pharmacology: Advances and Applications 2021:13 53–60                                           53
http://doi.org/10.2147/CPAA.S276085 
DovePress © 2021 Alruwaili et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms. 
php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the 
work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For 
permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
Clinical Pharmacology: Advances and Applications                               Dovepress
open access to scientific and medical research










































































Powered by TCPDF (www.tcpdf.org)
fatty liver disease (NAFLD), cancers (eg endometrial can-
cer), obstructive sleep apnea (OSA), depression, and 
osteoarthritis.7–11
The repetitive episodes of hunger and fullness are 
mainly controlled by the central nervous system (CNS). 
The subcortical areas of the brain such as the brainstem 
and the hypothalamus are the regions of the CNS respon-
sible for energy homeostasis control, which receive per-
ipheral neural and hormonal signals about nutritional state 
and adiposity.12 The arcuate nucleus (ARC) of the 
hypothalamus has an important role in the regulation of 
food consumption and energy homeostasis.13 There are 
two different groups of neurons responsible for appetite 
regulation in the ARC including the proopiomelanocortin 
(POMC) appetite-inhibiting/Anorexigenic neurons and the 
neuropeptide Y (NPY) and agouti-related peptide (AgRP) 
appetite stimulating/orexigenic co-expressing neurons.14 
Neural and hormonal signals from the periphery result in 
changes in the relative activity of these two neuronal 
subgroups and the release of their respective neuropep-
tides, subsequently influencing food intake and energy 
expenditure.15
Satiety gut hormones are part of the mechanisms by 
which the periphery inform the centre about energy balance. 
One of these satiety gut hormones is glucagon-like peptide 1 
(GLP-1), which is secreted from the intestinal mucosa of 
endocrine L cells in the ileum and colon in response to the 
food intake and presence of nutrients in the intestinal lumen. 
Once secreted, the half-life of GLP-1 is only a few minutes 
due to the rapid breakdown by dipeptidyl peptidase-4 (DPP- 
4).16,17 Liraglutide, a GLP-1 analogue, is 97% homologous 
to the amino acid sequence of endogenous human GLP-1. 
Liraglutide has a prolonged half-life of 13 hours because it is 
resistant to DPP-4 degradation. As a consequence, the sui-
table dose of liraglutide is once-daily.18 The receptors of 
liraglutide are Similar to endogenous GLP-1, liraglutide 
binds to and activates the GLP-1 receptor in the peripheral 
and central nervous system, pancreas, intestine, stomach, 
kidney, and heart.19
Mechanism of Action of Liraglutide 
on Food Intake Reduction
In addition to the action on pancreatic and gastric 
receptors, liraglutide acts on the brain’s subcortical 
areas to produce satiety.20,21 GLP-1 Receptors (GLP- 
1Rs) are located on the nodose ganglion of abdominal 
vagal afferent nerve fibers that terminate in the nucleus 
tractus solitarius (NTS) in the brainstem. Information 
from the NTS is transmitted to the hypothalamus and 
other forebrain regions through ascending second-order 
neurons. The results of rodent studies revealed that 
central or peripheral administration of GLP-1R ago-
nists decreases short-term food and water intake and 
causes body weight reduction.22 In rats and primates’ 
studies, GLP-1 receptors have been identified in differ-
ent areas of the brain, involving the hypothalamic 
nuclei and brainstem.23 The highest level of GLP-1 
receptor immunoreactivity is found in select brainstem 
and hypothalamic regions that control feeding, includ-
ing hypothalamic nuclei of the paraventricular and 
arcuate nucleus as well as the area postrema, NTS, 
and vagus dorsal motor nucleus.24 GLP-1 receptors 
are located in different areas of the brain including 
the parietal cortex, hypothalamus and medulla. 
Liraglutide activates these receptors in the brain that 
relate to highly desirable food signals in humans.25 
Box 1 summarises the Glucagon-like peptide receptors 
in the brain: controlling food intake and body weight.
GLP-1 also increases fullness. Peripheral GLP-1 
can reach the central nervous system at the level of 
the circumventricular organs.26 A 100-mm visual ana-
log scale assessed satiety in participants receiving 
GLP-1 analogues. Participants had to indicate their 
opinion using the following statements: “I cannot eat 
another bite” (satiety), “I am totally full” (fullness), 
and “I have never been more hungry” (hunger). 
Compared to the control group who received a saline 
infusion, the participants who received GLP-1 were 
more likely to report satiety and fullness and less likely 
to report hunger.27 The subjects with obesity who 
administered GLP-1 had a prolonged period of post-
prandial satiety and a slower rate of gastric emptying 
than subjects who received saline infusions.28 GLP-1 
also induced satiety in rodents, while the use of a GLP- 
1 receptor antagonist, exendin 9–39, caused these 
effects to be dissipated, supporting the role of the 
GLP-1 receptor in food intake. GLP-1 receptor’s 
mRNA has been identified in several areas of interest 
in appetitive behaviour and food intake, namely the 
paraventricular, arcuate nuclei, and supraoptic nuclei.29 
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Box 1 Glucagon-Like Peptide Receptors in the Brain: Controlling 
Food Intake and Body Weight
The nodose ganglion of abdominal vagal afferent nerve fibers
The area postrema
Nucleus tractus solitarius (NTS)
Hypothalamic nuclei of the paraventricular and arcuate nucleus which 
include: 
Pro-opiomelanocortin (POMC) appetite-inhibiting/Anorexigenic 
neurons. 
Neuropeptide Y (NPY) and agouti-related peptide (AgRP) appetite 
stimulating/orexigenic co-expressing neurons.
The mechanism of action of GLP-1 on food intake 
reduction is mainly mediated through both peripheral and 
central nervous system (CNS) pathways. Liraglutide 
directly stimulates POMC neurons and inhibits neuropep-
tide-Y (NPY) and Agouti-related peptide (AgRP) neurons 
in the arcuate nucleus resulting in a reduction in hunger 
and increases in fullness.30 These actions can also be 
associated with effects on other brain areas such as the 
mesolimbic system resulting in less food-induced reward 
signals and hence decreased appetitive or food-seeking 
behaviour.31 GLP-1 receptor agonists systemic administra-
tion slows gastric emptying, decreases food intake, and 
reduces body weight.22,32,33 Of note, in terms of desirable 
amount of weight loss, the Look AHEAD study showed 
that 5% weight loss did not reduce cardiovascular events, 
but that 10% weight loss was sufficient to achieve reduc-
tion in events.34
In rodent’s experimental follow-up study, fluorescently 
labeled liraglutide was used to assess if peripherally admi-
nistered liraglutide could reach brain regions that might be 
involved in its effects on food intake and body weight. 
Labeled liraglutide appeared exclusively in several brain 
regions that play an important role in the regulation of 
feeding including, the paraventricular nucleus of the 
hypothalamus and central nucleus of the amygdala. 
Surprisingly, the fluorescently labeled liraglutide was not 
detected in NTS, a brain region involved in GLP-1’s 
effects on food intake. This would suggest that liraglutide 
activation of NTS GLP-1Rs may be through an indirect 
rather than a direct pathway.35,36
Pharmacokinetic Properties
The liraglutide structure includes Arg 34 replacing Lys 34 
at the N-terminal and a fatty acid chain is added to Lys 
26.37 In contrast to natural GLP-1, this change allows for 
99% albumin binding, allowing liraglutide to escape glo-
merular filtration and extend its duration of action. Both 
self-association and decreased renal clearance of the pep-
tide results in an enhanced half-life of approximately 13 
hours after subcutaneous injection, compared with the 
very short half-life of native GLP-1. Liraglutide is 
detected in the urine and feces as a low level of metabo-
lites, suggesting slow degradation into small peptides, 
amino acids, and fatty acid fragments eliminated through 
the liver or the kidney.38 Pharmacokinetics of liraglutide 
have been studied in several sub-populations representing 
a variety of demographic variables. Overall, the only two 
factors impacting pharmacokinetics are body weight and 
sex. Two Phase III studies, one conducted in US and 
another in Asia showed a decrease in mean exposure 
(based on AUC values) as body weight increased.39,40 
However, there was a significant overlap in exposure 
values between individuals in subgroups of low and high 
body weight, hence dose adjustment according to body 
weight (or body mass index) is not required. In the two 
population pharmacokinetic analyses of the subjects, mean 
liraglutide exposure was greater for female than male 
individuals after correction for differences in body weight. 
As there was generally a large overlap in exposure values 
among individual male and female subjects, dose adjust-
ment according to sex is not considered to be 
meaningful.41,42
Liraglutide exposure is not related to age, the AUC 
(adjusted for body weight) was equivalent in young age 
groups (18–45 years, both included) and older age groups 
(age 65 years) in a single-dose study in healthy subjects.43 
Among children with type 2 diabetes, liraglutide exposure 
in age group 10–17 years is similar to that observed in 
adults.44
In the LEAD-6 trial, exenatide was directly compared 
with liraglutide to determine the efficacy and safety of each 
agent. Liraglutide has minimal impact on renal function due 
to its chemical structure.45 Liraglutide was also investigated 
in subjects with mild, moderate, severe, or no hepatic 
impairment. 40 Subjects received 0.75 mg of liraglutide as 
a single dose, and were evaluated after a 72-hours to deter-
mine if hepatic impairment influenced liraglutide’s kinetic 
and safety profile. The conclusion was that no hepatic or 
renal dosing adjustments are necessary with liraglutide.46
In a pooled analysis of Liraglutide Effect and Action in 
Diabetes (LEAD) clinical trials, low-level antibodies to 
liraglutide were detected (8.7 of patients taking 1.2mg 
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and 8.3% of patients taking 1.8mg). Anti-liraglutide anti-
body presence did not attenuate the glycemic response to 
liraglutide, and no patients with anti-liraglutide antibodies 
had serious or systemic immunologic adverse events.47
In vitro studies, liraglutide has shown a very low 
potential for pharmacokinetic drug–drug interactions 
related to cytochrome P450 (CYP). Although the slight 
prolongation in gastric emptying with liraglutide may 
affect the extent of absorption of co-administered drugs, 
no clinically relevant interactions were observed between 
steady-state liraglutide (1.8 mg/day) and single doses of 
insulin detemir, atorvastatin, griseofulvin, paracetamol, 
digoxin, lisinopril or oral contraceptives.12,13 When war-
farin is administered to patients receiving liraglutide, more 
frequent monitoring of the international normalized ratio is 
recommended, because interaction between the two drugs 
has not yet been evaluated.48
Clinical Impact of Liraglutide as 
Treatment of Obesity
Several studies were conducted in a large population of 
subjects with diabetes to evaluate liraglutide as a treatment 
for diabetes and found that it improved glycemic control 
and produced significant body weight loss.49 Liraglutide 
was firstly approved for the treatment of diabetes, and 
several studies were then conducted to evaluate it as 
a therapy for obesity. The 56 weeks SCALE Diabetes 
trial which included 846 participants with body mass 
index of 27 or greater demonstrated that both the 3.0 and 
1.8 mg subcutaneous doses of liraglutide performed better 
than placebo, with percentage body weight reduction of 
6%, 5% and 2%, respectively. A total of 50% of indivi-
duals on 3.0 mg liraglutide showed ≥5.0% of body weight 
reduction, compared with 36% in individuals on the lower 
dose and 14% on the placebo. A total of 23%, 14% and 
4% of participants lost >10% body weight in the three 
arms, respectively.50 The SCALE Obesity and Prediabetes 
trial involving 3731 patients showed that the once-daily 
subcutaneous dose of 3.0 mg liraglutide, when used as an 
adjunct to a reduced-calorie diet and increased physical 
activity, was associated with significant weight reduction 
in adult with overweight or obesity who did not have 
diabetes. The response to liraglutide was similar in sub-
jects with prediabetes versus one without prediabetes, and 
was similar across baseline Body mass index (BMI) cate-
gories. The mean weight change with liraglutide was 8 kg 
and was generally maintained for 1 year, as long as the 
patients continued treatment and weight regain usually 
follows after treatment discontinuation.51
The SCALE Sleep Apnoea study demonstrated 
a reduction in weight and improvement in Apnea 
Hypopnea Index (AHI) in the liraglutide group compared 
to placebo.52
Weight loss of more than 10% in individuals with obe-
sity starts to improve other obesity-related-complications, 
such as reducing cardiovascular disease risk and non- 
alcoholic steatohepatitis.53 The treatment regimens to help 
patients achieve at least 7%weight loss could help patients 
achieve remission of T2DM and prevent patients with pre-
diabetes from progressing further.54 The effect of liraglutide 
in the risk reduction of T2DM in patients with prediabetes 
was reported in the SCALE prediabetes trial. At week 160 
of the study, 2% of subjects treated with subcutaneous 
liraglutide 3.0 mg developed T2DM compared to 6% of 
subjects in the placebo arm. Liraglutide showed a 80% 
reduction in T2DM risk and the estimated time to onset of 
T2DM over 160 weeks was 2.7 times longer with the 
liraglutide group than with the placebo group.53 The results 
of this trial confirmed that liraglutide as a weight loss agent 
improves various cardio-metabolic parameters and reduces 
the risk of diabetes in individuals with obesity and 
prediabetes.51
In a large, double blind, multicenter trial, 9340 subjects 
with type 2 diabetes and high cardiovascular risk were 
randomised to receive subcutaneous liraglutide 1.8 mg 
daily or placebo and followed for 3.8 years. Death from 
cardiovascular causes, nonfatal myocardial infarction, or 
nonfatal stroke was the study’s primary outcome. The 
primary outcome occurred in fewer subjects in the liraglu-
tide arm (13%) than in the placebo arm (15%). Fewer 
overall deaths (HR 0.85) as well as cardiovascular deaths 
(HR 0.78) were reported in the liraglutide group compared 
with placebo. Importantly, there was no increase in hospi-
talisation due to heart failure in the liraglutide group. This 
study used liraglutide dose of 1.8mg as indicated for 
T2DM and not the dose of 3.0mg indicated for the treat-
ment of obesity.55
In the SCALE maintenance, trial patients with obesity 
or overweight who lost ≥5% of their initial weight during 
a low calorie-diet were randomly assigned to 3.0 mg sub-
cutaneous dose of liraglutide or placebo for 56 weeks. The 
study results showed that liraglutide compared with pla-
cebo, improved weight loss maintenance and induced 
additional reductions in cardiovascular disease (CVD) 
risk factors such as a reduction in systolic blood pressure, 
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fasting plasma glucose and high-sensitivity C-reactive pro-
tein (CRP).56 At week 56 of the study, participants in the 
liraglutide arm experienced an additional weight reduction 
of 6% from the run-in period compared with a 0.05% 
weight reduction in the placebo arm. The percentage of 
patients who maintained their weight loss from the run-in 
period was also higher in the liraglutide arm (81%) com-
pared with placebo (49%).56 Another study in primary care 
provides the first evaluation of the effect of intensive 
behavioral therapy (IBT) delivered alone (with placebo) 
or in combination with liraglutide 3.0mg. After 1 year, 
mean weight loss in patients who received liraglutide 
3.0 mg plus IBT was 7.5% compared to a 4% in those 
who received IBT alone.57
Safety and Tolerability
Generally, GLP-1 agonists and analogues are well toler-
ated. The most common side effect is nausea which is 
more frequent in the early stages of therapy.45,49 Other 
gastrointestinal complaints such as constipation, vomiting, 
and diarrhoea are less common than nausea.45,49,58 While 
these side effects are not a serious health concern, they 
may contribute to a patient’s decision to discontinue ther-
apy. Other side effects include a small but sustained 
increase in heart rate (2–4 beat/min), this chronotropic 
effect of liraglutide may be mediated through the GLP-1 
receptor on the sinoatrial node. Despite this, studies have 
reported that GLP-1 agonists through its beneficial effects 
on weight loss, improvement in metabolic parameters, and 
blood pressure reduction has a positive effects on the 
cardiovascular outcomes.59 Accordingly, the LEADER 
study demonstrated a significant reduction in cardiovascu-
lar mortality after liraglutide.55
Liraglutide is associated with a low risk of hypogly-
caemia. Very few minor or major hypoglycaemic episodes 
have been reported with liraglutide across the LEAD stu-
dies. For example, as a monotherapy, no major hypogly-
caemia incidents were reported and only 8% of patients 
treated with liraglutide 1.8 mg reported minor hypoglycae-
mia (plasma glucose <3.1 mmol/l), corresponding to 0.25 
episodes/subject-year. In contrast, 24.2% of glimepiride- 
treated subjects reported minor hypoglycaemia; the rate 
was þ1.96 episodes/subject-year.60 No major hypoglycae-
mia was reported when liraglutide was used in combina-
tion therapy with metformin.61 The LEADER study 
showed that nephropathy events were 22% lower after 
liraglutide therapy compared to placebo, but there was no 
significant difference in retinopathy events.55
Few minor and major hypoglycaemic episodes have 
been reported with liraglutide across the LEAD studies.28 
For example, as a monotherapy, no major hypoglycaemia 
incidents were reported and only 8% of patients treated 
with liraglutide 1.8 mg reported minor hypoglycaemia 
(plasma glucose <3.1 mmol/l), corresponding to 0.25 epi-
sodes/subject-year. In contrast, 24.2% of glimepiride- 
treated subjects reported minor hypoglycaemia; the rate 
was þ1.96 episodes/subject-year (p < 0.0001).28 Only one 
major hypoglycaemic episode (blood glucose ¼ 3.0 mmol/ 
l) was reported when liraglutide was used in combination 
with one OAD.
Additionally, since GLP-1 receptor agonists can cause 
significant weight loss in a short period, cholecystitis has 
been reported in 3 in 100 patients. A known serious side 
effect of gallstone formation is pancreatitis. Generally, 
weight loss by any modality (diet, medication or surgery) 
can result in gallstone formation and gallstones are 
a known aetiological factor for pancreatitis even after 
bariatric surgery.62
However, in a clinical trial involving approximately 
4500 patients, only seven cases of pancreatitis were 
reported which was not more than what can be expected 
in this population of patients. Reviews of clinical data by 
the European Medicine Agency (EMA) concluded that 
treatment with GLP-1 receptor agonists did not increase 
the risk of developing pancreatitis.63 Rodent studies 
demonstrated proliferation of thyroid C-cells and tumor 
formation following long-term treatment with GLP-1 ago-
nist compounds, but the potential risk of thyroid cancer 
has not been shown in non-human primates or humans.64 
This may be because humans have a lower density of 
GLP-1 receptors on thyroid C cells.65 However, the side 
effects of prolonged use of higher doses of liraglutide such 
as those used for weight loss treatment in humans requires 
long-term surveillance.
In conclusion, the GLP-1 analogue, liraglutide, 
decreases food intake, promotes weight loss, and improves 
metabolic function parameters. The primary mechanism of 
GLP-1 effect on food intake, metabolism and weight 
reduction is mainly due to its actions on peripheral 
(vagal) and central pathways and activation of hindbrain 
and hypothalamus, and those brain regions associated with 
motivation and reward processes. With the high preva-
lence of obesity and its negative impacts on the quality 
of life, there is a need for therapies that will produce 
sustained double digit weight loss. Bariatric surgery is 
currently the most effective treatment option for diabetes 
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and obesity. Comparing the clinical efficacy of bariatric 
surgery and liraglutide it is clear that surgery is superior to 
liraglutide for both body weight reduction and improve-
ments in metabolic parameters.66 Despite this, many indi-
viduals are not eligible for surgery and would benefit from 
anti-obesity medications. Liraglutide produces significant 
weight loss in patients with and without T2DM and has 
tolerable side effects. Liraglutide is an attractive treatment 
option, although the GLP-1 class of medication may hold 
even more promise in the near future.
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